long intergenic non-protein coding RNA 1168Genealiases: []
Q-omics provides the consensus-scored LINC01168 profile across patient tissues and cancer cell-line models. LINC01168 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01168 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, LINC01168 RNA expression shows 8,329 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, UCEC, and KIRP as cancer lineages where LINC01168 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01168 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01168 survival associations across molecular data types. LINC01168 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01168 RNA expression–survival associations across cancer types. High LINC01168 expression shows unfavorable associations in LUAD, UCEC, CHOL and COAD, but favorable associations in MESO and SARC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01168 RNA expression.
This table summarizes LINC01168 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01168. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01168 shows lower tumor expression in UCEC, LUAD, KICH, LUSC and KIRC and higher tumor expression in READ. The UCEC box plot shows higher LINC01168 RNA expression in normal versus tumor tissue (log2 FC = −0.174, t-test p < 0.001).
This table shows molecular features associated with LINC01168 in patient tissues and cancer cell lines. In patient samples, LINC01168 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
